knowledge -WSS

knowledge

author：comprehensive 2025-10-01 18:34:19 - browse：9289

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Cancer drug shortages' outsize impact on ovarian cancer patients

WSS

The biotech scorecard for Q1: 17 stock

Feng Zhang CRISPR delivery startup lays off quarter of staff

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Antibiotic resistance and the global rise in human conflict

ActiGraph execs on goal of drug approvals with digital endpoints

entertainment

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

New air purifier tech could be key to improving indoor air quality

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Heart attack and stroke risk calculators need revising

A neonatal nurse in a British hospital has been found guilty of killing 7 babies

Psychedelics group wrestles with new pharma identity

Congress must give Medicare recipients genetic counseling access

As demand for Covid shots wanes, Moderna seeks its next success

Beware the threat of staffing cuts at the CDC

In age of alternative facts, a scholarly course on calling out crap

Feng Zhang, Grail founder join forces on new gene editing startup

hotspot

As Maui death toll rises, number of missing remains unclear

ActiGraph execs on goal of drug approvals with digital endpoints

Clinical trials must include more disabled people

New weight loss drugs work. But how can they best be used?

The pain doctors face in trying to build their families

The boys, now 6, who are gene therapy’s ‘edge case’ problem

explore

focus

leisure time

explore